Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 2503 + Gemcitabine in Pancreatic Cancer
NCT00006467Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2001
- Primary completion
- Jan 2004
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of H-Ras antisense oligodeoxynucleotide ISIS 2503 in pancreatic adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 6 months. Started Feb 2001; status: completed.
02
Drugs
H-Ras antisense oligodeoxynucleotide ISIS 2503
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00006467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006467.